Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Toyama, T. et al.

Toyama, Hoshizaki, Seki, Isobe, Adachi, Naito, Oshima, Taniguchi,

Efficacy of amiodarone treatment on cardiac symptom, function, and sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with beta-blocker therapy.

BACKGROUND: Amiodarone, which is an antiarrhythmic drug used to treat life-threatening arrhythmias, is effective in patients with chronic heart failure. However, its effectiveness compared with beta-blockers has not yet been reported. METHODS AND RESULTS: In 30 patients (mean age, 57 +/- 13 years) with dilated cardiomyopathy, we compared 15 patients receiving amiodarone (group A) with 15 patients receiving metoprolol (group B). Before and after 1 year of treatment, cardiac iodine 123 metaiodobenzylguanidine uptake was assessed from the total defect score, heart-to-mediastinum activity ratio based on delayed images, and washout rate. New York Heart Association class and echocardiographic left ventricular ejection fraction were also assessed. In both groups the total defect score decreased (from 25 +/- 11 to 16 +/- 10 in group A, P <.01; from 26 +/- 10 to 18 +/- 11 in group B, P <.01), the heart-to-mediastinum activity ratio increased (from 1.63 +/- 0.16 to 1.81 +/- 0.29 in group A, P <.01; from 1.63 +/- 0.21 to 1.85 +/- 0.3 in group B, P <.01), and the washout rate decreased (from 51% +/- 12% to 38% +/- 14% in group A, P <.01; from 48% +/- 11% to 37% +/- 8% in group B, P <.01). Left ventricular ejection fraction increased (from 30% +/- 9% to 42% +/- 11% in group A, P <.01; from 26% +/- 7% to 46% +/- 16% in group B, P <.01) and New York Heart Association functional class improved (from 3.1 +/- 0.5 to 1.8 +/- 0.7 in group A, P <.01; from 2.9 +/- 0.5 to 1.7 +/- 0.6 in group B, P <.01). CONCLUSION: Amiodarone treatment can improve cardiac symptom, function, and sympathetic nerve activity, as evaluated by I-123 metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy, which improves to a similar extent with beta-blocker treatment.[1]

References

Efficacy of amiodarone treatment on cardiac symptom, function, and sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with beta-blocker therapy. Toyama, T., Hoshizaki, H., Seki, R., Isobe, N., Adachi, H., Naito, S., Oshima, S., Taniguchi, K. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. (2004) [Pubmed]

Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.